ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 0925

Macrophages Produce Bone Anabolic Factors in Settings of Inflammation-Induced Bone Formation
Abstract Number: 0926

Macrophages and Nociceptor Neurons Form a Sentinel Unit Around Fenestrated Capillaries to Defend the Synovium from Systemic Challenges
Abstract Number: 0927

Synovial Macrophage Heterogeneity and Dynamics in Steady Stateand Rheumatoid Arthritis Mouse Model Time Course
Abstract Number: 0928

In Vitro Study of Fibroblast-Like Synoviocytes and Macrophages-Like Synoviocytes Isolated from Rheumatoid Arthritis, Psoriatic Arthritis Patients and Healthy Subjects
Abstract Number: 0929

UVB-Induced Keratinocyte-Derived Extracellular Vesicles: Cytokeratin 10 as a Marker of Epidermal Origin
Abstract Number: 0930

The Common Form of the Inflammatory Skin Disease Hidradenitis Suppurativa Is Associated with Low Nicastrin Expression in Dermal Fibroblasts
Abstract Number: 0931

Salivary Granular Convoluted Tubules Contribute to Maintain Tissue-specific Tolerance – Implications for the Development of Murine Sjögren´s Syndrome
Abstract Number: 0932

IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model
Abstract Number: 0933

NLRP3 Inflammasome Promotes Release of Peptidyl Arginine Deiminases2 and 4 from Human Neutrophils
Abstract Number: 0934

Screening NLRP3 Drug Candidates in Clinical Development:Lessons from Existing and Emerging Technologies
Abstract Number: 0935

Molecular Degraders of Extracellular Protein (MoDEsTM) Rapidly and Effectively Remove Interstitial IgG and Disease-Relevant Immune Complexes Through Endo-lysosomal Degradation in the Liver
Abstract Number: 0936

Schnurri-3 Inhibition Protects from NF-kB-induced Bone Loss in Inflammatory Arthritis
Abstract Number: 0937

A Novel Quantitative Method Reveals Bone-Structural Changes During Course of Inflammatory Arthritis
Abstract Number: 0938

Group 2 Innate Lymphoid Cells Promote T Cell Activation and Development of Autoimmune Arthritis
Abstract Number: 0939

A Joint-targeting Peptide Enhances the Therapeutic Efficacy of Liposomal Drug Delivery in Experimental Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].